本帖最后由 老马 于 2012-1-13 21:20 编辑
9 E+ y2 \$ ]' u+ w# r2 R$ _- }; T$ p' r- l, a/ K- i2 k4 o
爱必妥和阿瓦斯丁的比较
+ W7 X" |) x- n, U) O- v: o5 @
& l( [. S3 e) ^6 V6 d3 L
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 G0 W; `9 n+ v
( W( n; W2 C! g) [2 T2 d
9 I* X% V @/ d: @& R
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/" H5 m' Y+ B: Y
==================================================8 a6 W8 o" }" C' ]8 h" p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) v* `, M i! |6 v9 w- e3 d q, p
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. i# Y! `' x* H5 JResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.7 J+ q& ^& O3 |! R0 j1 ]: l
|